                         SEQUENCE LISTING

<110>  Tel HaShomer Medical Research Infrastructure and Services
       Ltd.
       MAGGIO, Nicola
       CHAPMAN, Joab
       SHAVIT STEIN, Efrat
 
<120>  NOVEL MOLECULES FOR THE TREATMENT OF INFLAMMATION

<130>  70127

<150>  US 62/345,802
<151>  2016-06-05

<160>  59    

<170>  PatentIn version 3.5

<210>  1
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  1

Ala Asn Ser Phe 
1               


<210>  2
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  2

Ala Asn Ala Phe 
1               


<210>  3
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (6)..(7)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  3

Ala Asn Ser Phe Leu Glu Glu Leu Arg 
1               5                   


<210>  4
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (6)..(7)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  4

Ala Asn Ala Phe Leu Glu Glu Leu Arg 
1               5                   


<210>  5
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  5

Glu Glu Ala Lys 
1               


<210>  6
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  6

Glu Glu Ala Arg 
1               


<210>  7
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  7

Glu Glu Ala Lys Glu Ile Phe 
1               5           


<210>  8
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  8

Glu Glu Ala Arg Glu Ile Phe 
1               5           


<210>  9
<211>  20
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  9
ccgaaagggc aacctagagc                                                   20


<210>  10
<211>  19
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  10
ggcccagaac acgtctgtg                                                    19


<210>  11
<211>  16
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  11
gtggccggga atgcaa                                                       16


<210>  12
<211>  25
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  12
aacccttcat tgtcttcgtt aatga                                             25


<210>  13
<211>  22
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  13
accgtgaggc ttggtgagta tg                                                22


<210>  14
<211>  20
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  14
acgcactcat ttcgagcaac                                                   20


<210>  15
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  15
tgaacccccg ctcattcttt c                                                 21


<210>  16
<211>  22
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  16
ccagcaggac gctttcattt tt                                                22


<210>  17
<211>  23
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  17
tgaaagactt gctcgagatg tca                                               23


<210>  18
<211>  20
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  18
cacacagagg gccacaatgt                                                   20


<210>  19
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (6)..(7)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  19

Ala Asn Ser Phe Leu Glu Glu Met Lys 
1               5                   


<210>  20
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  20

Glu Glu Ala Arg Glu Val Phe 
1               5           


<210>  21
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (6)..(7)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  21

Ala Asn Thr Phe Leu Glu Glu Val Arg 
1               5                   


<210>  22
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  22

Glu Glu Ala Phe Glu Ala Leu 
1               5           


<210>  23
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (6)..(7)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  23

Asn Ser Gly Lys Leu Glu Glu Phe Val 
1               5                   


<210>  24
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  24

Glu Glu Ala Arg Glu Val Phe 
1               5           


<210>  25
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (6)..(7)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  25

Ala Asn Ser Leu Leu Glu Glu Thr Lys 
1               5                   


<210>  26
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  26

Glu Glu Ala Arg Glu Val Phe 
1               5           


<210>  27
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (6)..(7)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  27

Gly Ser Tyr Leu Leu Glu Glu Leu Phe 
1               5                   


<210>  28
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  28

Glu Glu Ala Arg Glu Val Phe 
1               5           


<210>  29
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  29

Ala Asn Thr Phe 
1               


<210>  30
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  30

Glu Glu Ala Phe 
1               


<210>  31
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  31

Asn Ser Gly Lys 
1               


<210>  32
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  32

Ala Asn Ser Leu 
1               


<210>  33
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  33

Gly Ser Tyr Leu 
1               


<210>  34
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  34

Ala Asn Ser 
1           


<210>  35
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  35

Asn Ser Phe 
1           


<210>  36
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  36

Ser Phe Leu 
1           


<210>  37
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  may be gamma-carboxylated

<400>  37

Phe Leu Glu 
1           


<210>  38
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (2)..(3)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  38

Leu Glu Glu 
1           


<210>  39
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  39

Glu Glu Leu 
1           


<210>  40
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  40

Glu Leu Arg 
1           


<210>  41
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  41

Ala Asn Ala 
1           


<210>  42
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  42

Asn Ala Phe 
1           


<210>  43
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  43

Ala Phe Leu 
1           


<210>  44
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  44

Glu Glu Ala 
1           


<210>  45
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  45

Glu Ala Lys 
1           


<210>  46
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  may be gamma-carboxylated

<400>  46

Ala Lys Glu 
1           


<210>  47
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  47

Lys Glu Ile 
1           


<210>  48
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  48

Glu Ile Phe 
1           


<210>  49
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  49

Glu Ala Arg 
1           


<210>  50
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  may be gamma-carboxylated

<400>  50

Ala Arg Glu 
1           


<210>  51
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal modification: Amide or other stabilizing moiety

<400>  51

Arg Glu Ile 
1           


<210>  52
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X can be either Gly, Ala, Val, Leu or Ile

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X can be either Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, Tyr 
       or Cys

<220>
<221>  MISC_FEATURE
<222>  (2)..(3)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  C-terminal modification: Amide or other stabilizing moiety

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X can be either Gly, Ala, Val, Leu, Ile, Phe, Trp, Pro, Met, Phe,
       Tyr or Trp

<400>  52

Xaa Xaa Xaa Xaa 
1               


<210>  53
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Isolated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal modification: Tosyl  or other peptidase activity 
       protecting moiety

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  X is an acidic polar amino acid: Asp or  Glu

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  may be gamma-carboxylated

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  X  is a non-polar, aliphatic amino acid: Gly, Ala, Val, Leu or 
       Ile

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  C-terminal modification: Amide or other stabilizing moiety

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  may be gamma-carboxylated

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa can be any naturally occurring amino acid

<400>  53

Xaa Xaa Xaa Xaa 
1               


<210>  54
<211>  20
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  54
cctatgagcc agccagaatc                                                   20


<210>  55
<211>  20
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  55
gcaggacgct ttcatttttc                                                   20


<210>  56
<211>  20
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  56
gcagctcaat gcctacaacc                                                   20


<210>  57
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  57
ctgtttggct ccctttcatg t                                                 21


<210>  58
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  58
agatggatag tgaccgcaag c                                                 21


<210>  59
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  59
gtcatgttca cccatcacca c                                                 21


